Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer.
Pharmaceutics
; 14(7)2022 Jul 21.
Article
in En
| MEDLINE
| ID: mdl-35890409
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Guideline
Language:
En
Journal:
Pharmaceutics
Year:
2022
Document type:
Article
Affiliation country:
Países Bajos
Country of publication:
Suiza